Browse > Article

Applying Inhaled Furosemide for Refractory Breathlessness in Terminally-ill Cancer Patients - Based on Seminar of Palliative Medicine Research Group, The Korean Academy of Family Medicine -  

Hwang, In-Cheol (Department of Family Medicine, Gachon University Gil Hospital)
Lee, Min-Kyu (Department of Family Medicine, Gachon University Gil Hospital)
Kim, Kyoung-Kon (Department of Family Medicine, Gachon University Gil Hospital)
Lee, Kyoung-Sik (Department of Family Medicine, Gachon University Gil Hospital)
Suh, Heuy-Sun (Department of Family Medicine, Gachon University Gil Hospital)
Publication Information
Journal of Hospice and Palliative Care / v.13, no.4, 2010 , pp. 252-256 More about this Journal
Abstract
Breathlessness is a frequent and distressing symptom in terminal cancer patients. Refractory breathlessness is defined as a state that does not respond to conventional disease-specific therapy with an exclusion of reversible underlying causes, and the main classes of symptomatic drug treatments include opioids and benzodiazepines. Korean Family Medicine Palliative Medicine Research Group discussed two terminal cancer patients in whom severe breathlessness with different causes were treated with inhalation of nebulized furosemide, which is an emerging option of palliative treatment. It still remains unclear how it becomes effective or how much it is effective, therefore, its routine use seems to be somewhat early. Nevertherless, if a patient with intractable breathlessness does not have a marked obstructive airway lesion, its use should be considered. Based on the discussion in the seminar, we want to share our experience of the application of inhaled furosemide with other palliative care practitioners and strongly recommend further research on this topic in the future.
Keywords
Dyspnea; Furosemide; Neoplasms;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Kohara H, Ueoka H, Aoe K, Maeda T, Takeyama H, Saito R, et al. Effect of nebulized furosemide in terminally ill cancer patients with dyspnea. J Pain Symptom Manage 2003;26(4):962-7.   DOI   ScienceOn
2 Ben-Aharon I, Gafter-Gvili A, Paul M, Leibovici L, Stemmer SM. Interventions for alleviating cancer-related dyspnea: a systematic review. J Clin Oncol 2008;26(14):2396-404.   DOI   ScienceOn
3 Thomas JR, von Gunten CF. Clinical management of dyspnoea. Lancet Oncol 2002;3(4):223-8.   DOI   ScienceOn
4 Dorman S, Byrne A, Edwards A. Which measurement scales should we use to measure breathlessness in palliative care? A systematic review. Palliat Med 2007;21(3):177-91.   DOI   ScienceOn
5 Newton PJ, Davidson PM, Macdonald P, Ollerton R, Krum H. Nebulized furosemide for the management of dyspnea: does the evidence support its use? J Pain Symptom Manage 2008;36(4):424-41.   DOI   ScienceOn
6 Wilcock A, Walton A, Manderson C, Feathers L, El Khoury B, Lewis M, et al. Randomised, placebo controlled trial of nebulised furosemide for breathlessness in patients with cancer. Thorax 2008;63(10):872-5.   DOI   ScienceOn
7 Mercadante S, Casuccio A, Fulfaro F. The course of symptom frequency and intensity in advanced cancer patients followed at home. J Pain Symptom Manage 2000;20(2):104-12.   DOI   ScienceOn
8 Reuben DB, Mor V. Dyspnea in terminally ill cancer patients. Chest 1986;89(2):234-6.   DOI   ScienceOn
9 Cachia E, Ahmedzai SH. Breathlessness in cancer patients. Eur J Cancer 2008;44(8):1116-23.   DOI   ScienceOn
10 Gwak JI, Suh SY. The assessment tools in palliative medicine. Korean J Hosp Palliat Care 2009;12(4):177-93.   과학기술학회마을
11 American Thoracic Society. Dyspnea. Mechanisms, assessment, and management: a consensus statement. American Thoracic Society. Am J Respir Crit Care Med 1999;159(1):321-40.   DOI   ScienceOn
12 Stone P, Kurowska A, Tookman A. Nebulized frusemide for dyspnoea. Palliat Med 1994;8(3):258.   DOI   ScienceOn
13 Bianco S, Vaghi A, Robuschi M, Pasargiklian M. Prevention of exercise-induced bronchoconstriction by inhaled frusemide. Lancet 1988;2(8605):252-5.